Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo. Subscription Required You must be a subscriber to access all of this content. View Subscriptions Already a subscriber? Log in...
